Cancer
Breakthrough in Immunotherapy for Non-Small Cell Lung Cancer
A new study has made a significant advancement in immunotherapy for patients with ALK/EGFR wt resectable non-small cell lung cancer (NSCLC). Researchers from the IRCCS Regina Elena National Cancer Institute used a combination of deep molecular profiling, spatial transcriptomics, and serum proteomic profiling to achieve a complete pathologic response